EDSA Edesa Biotech, Inc.

3.895USD+4.70%Mkt Cap: 52.63M $P/E: —

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It dev…

HeadlineSourceTime
Older
3 Small Cap Biotech Stocks Trading At A Discount With Late Stage Clinical Catalysts

Looking for biotech stocks with upside that could help people fight illness? Here are three that analysts think might be worth a look.

Simply Wall St.
Edesa Biotech Stock Sinks After Fresh Capital Raise

Edesa Biotech, Inc. (NASDAQ:EDSA) shares fell nearly 13% in Thursday premarket trading after the company priced a $25 million public stock offering. Edesa Biotech shares fell 18.27% to $4.70 in Wednesday’s after-market session, putting the stock on traders’ radars. The move followed the company’s Q3 earnings release, which came out four days earlier, according to Benzinga’s after-hours movers recap. What Is Edesa Biotech’s Financing Deal? Edesa is raising fresh capital via an equity offering of

Benzinga